Ronald Vender

4.5k total citations · 1 hit paper
139 papers, 2.7k citations indexed

About

Ronald Vender is a scholar working on Immunology, Dermatology and Pathology and Forensic Medicine. According to data from OpenAlex, Ronald Vender has authored 139 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Immunology, 77 papers in Dermatology and 29 papers in Pathology and Forensic Medicine. Recurrent topics in Ronald Vender's work include Psoriasis: Treatment and Pathogenesis (94 papers), Dermatology and Skin Diseases (61 papers) and Autoimmune Bullous Skin Diseases (28 papers). Ronald Vender is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (94 papers), Dermatology and Skin Diseases (61 papers) and Autoimmune Bullous Skin Diseases (28 papers). Ronald Vender collaborates with scholars based in Canada, United States and Germany. Ronald Vender's co-authors include Charles Lynde, Marc Bourcier, Yves Poulin, Francis Murphy, Denis Sasseville, Channy Muhn, Sam Khalil, Kim Papp, Andrew Blauvelt and Andreas Pinter and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Ronald Vender

135 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

2021 170 citations Peter Foley, Andreas Pinter et al. profile →

Peers

Countries citing papers authored by Ronald Vender

Since Specialization

Citations

This map shows the geographic impact of Ronald Vender's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald Vender with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald Vender more than expected).

Fields of papers citing papers by Ronald Vender

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald Vender. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald Vender. The network helps show where Ronald Vender may publish in the future.

Co-authorship network of co-authors of Ronald Vender

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald Vender. A scholar is included among the top collaborators of Ronald Vender based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald Vender. Ronald Vender is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Considerations for defining and diagnosing generalized pustular psoriasis 2024 ·Journal of the European Academy of Dermatology and Venereology ·Vimal H. Prajapati, Charles Lynde, Melinda Gooderham, Chih-ho Hong, Mark G. Kirchhof, Perla Lansang, (unknown), Irina Turchin, Ronald Vender, Jensen Yeung, Kim Papp	4
2	A systematic review of recent randomized controlled trials for palmoplantar pustulosis 2024 ·Journal of Dermatological Treatment ·(unknown), (unknown), Tiago Torres, Ronald Vender	0
3	Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents 2024 ·Pharmaceutics ·Anastasia Drakos, Tiago Torres, Ronald Vender	15
4	Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 52-week multicenter retrospective study 2024 ·Journal of the American Academy of Dermatology ·(unknown), (unknown), (unknown), (unknown), Jorge R. Georgakopoulos, Khalad Maliyar, (unknown), (unknown), (unknown), (unknown), Ronald Vender, Jensen Yeung, Vimal H. Prajapati	5
5	42592 Baseline Characteristics and Interim Month 12 mNAPSI Results in Patients with Moderate-to- Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics in the Psoriasis Study of Health Outcomes (PSoHO) 2023 ·Journal of the American Academy of Dermatology ·Alexander Egeberg, Andreas Pinter, Ronald Vender, (unknown), Alan Brnabic, Christopher F. Schuster, (unknown), Catherine Reed, Elisabeth Riedl, L. Puig	1
6	Speed of clinical improvement in the real‐world setting from patient‐reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks 2023 ·Journal of the European Academy of Dermatology and Venereology ·Adam Reich, Andreas Pinter, Julia‐Tatjana Maul, Ronald Vender, Tiago Torres, Alan Brnabic, (unknown), Catherine Reed, Christopher Schuster, Elisabeth Riedl	6
7	Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial 2023 ·British Journal of Dermatology ·Diamant Thaçi, Ronald Vender, Menno A. de Rie, Curdin Conrad, David M. Pariser, Bruce Strober, Veerle Vanvoorden, Maggie Haitian Wang, Cynthia Madden, Dirk De Cuyper, Alexa B. Kimball	16
8	Plaque psoriasis and morphea in a patient on ustekinumab: A case report 2023 ·SHILAP Revista de lepidopterología ·(unknown), Ronald Vender	2
9	78 A Phase 2, randomized, placebo-controlled, dose-ranging study of oral JNJ-77242113 for moderate-to-severe plaque psoriasis: Efficacy of overall and scalp psoriasis responses from FRONTIER 1 2023 ·Journal of Investigative Dermatology ·Robert Bissonnette, Andreas Pinter, Laura K. Ferris, Sascha Gerdes, Phoebe Rich, Ronald Vender, Ya‐Wen Yang, Megan Miller, Yaung‐Kaung Shen, Cynthia Marie Carver DeKlotz, Kim Papp	3
10	Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel 2023 ·Dermatology and Therapy ·Kim Papp, Barbara Melosky, Sandeep Sehdev, Sébastien J. Hotte, Jennifer Beecker, Mark G. Kirchhof, Irina Turchin, Jan Dutz, Melinda Gooderham, Robert Gniadecki, Chih-ho Hong, Jo Lambert, Charles Lynde, Vimal H. Prajapati, Ronald Vender	10
11	A Psoriatic Patient-Based Survey on the Understanding of the Use of Vaccines While on Biologics During the COVID-19 Pandemic 2021 ·Journal of Cutaneous Medicine and Surgery ·(unknown), Ronald Vender	3
12	Management of pediatric generalized pustular psoriasis using biologics: An evidence-based review 2021 ·Journal of the American Academy of Dermatology ·Muskaan Sachdeva, (unknown), Asfandyar Mufti, Jensen Yeung, Ronald Vender, Nadia Luca, Päivi Miettunen, (unknown), (unknown), Vimal H. Prajapati	7
13	Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study 2021 ·JAAD International ·Yuliya Lytvyn, Asfandyar Mufti, (unknown), Muskaan Sachdeva, Justin D. Lu, (unknown), Vimal H. Prajapati, Ronald Vender, Jensen Yeung	2
14	A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial* 2020 ·British Journal of Dermatology ·Andrew Blauvelt, C. Leonardi, Boni E. Elewski, Jeffrey Crowley, Lyn Guenther, Melinda Gooderham, Richard G. Langley, Ronald Vender, Andreas Pinter, C.E.M. Griffiths, Yayoi Tada, Hany Elmaraghy, Renata Gontijo Lima, Gaia Gallo, L. Renda, Russel Burge, (unknown), Baojin Zhu, Kim Papp, (unknown)	73
15	Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study 2019 ·Journal of Cutaneous Medicine and Surgery ·Christine Fahim, (unknown), Marc Bourcier, Steven J. Glassman, Melinda Gooderham, Lyn Guenther, Wayne Gulliver, Charles Lynde, Yves Poulin, Melanie D. Pratt, Neil H. Shear, Ronald Vender, Scott R. Walsh, (unknown)	2
16	Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice 2017 ·British Journal of Dermatology ·Arnon D. Cohen, Jashin J. Wu, L. Puig, Sergio Chimenti, Ronald Vender, Murlidhar Rajagopalan, Ricardo Romiti, Claudia de la Cruz, Lone Skov, Claus Zachariae, Helen Young, Peter Foley, Joelle M. van der Walt, Luigi Naldi, Errol P. Prens, Andrew Blauvelt	33
17	Psoronychomycosis 2016 ·Journal of Cutaneous Medicine and Surgery ·(unknown), Ronald Vender, (unknown), (unknown)	5
18	Paradoxical, Cupping-Induced Localized Psoriasis: A Koebner Phenomenon 2015 ·Journal of Cutaneous Medicine and Surgery ·(unknown), Ronald Vender, (unknown), (unknown)	14
19	Double-Blinded, Vehicle-Controlled Proof of Concept Study to Investigate the Recurrence of Inflammatory and Noninflammatory Acne Lesions Using Tretinoin Gel (Microsphere) 0.04% in Male Patients after Oral Isotretinoin Use 2012 ·Dermatology Research and Practice ·(unknown), Ronald Vender, (unknown), (unknown)	9
20	Antihistamines in the Treatment of Atopic Dermatitis 2003 ·Journal of Cutaneous Medicine and Surgery ·(unknown), Ronald Vender	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact